Can a vitamin D2 blast speed up recovery in lymphoma patients?
NCT ID NCT07366450
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a high-intensity loading dose of vitamin D2 to standard weekly dosing in 52 patients with newly diagnosed aggressive non-Hodgkin lymphoma who are also receiving standard chemotherapy. The goal is to see if the high-dose approach normalizes vitamin D levels faster and safely. Participants will be randomly assigned to one of the two dosing strategies and monitored for vitamin D levels, safety, and treatment outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ergocalciferol (vitamin D2)
What this could lead to
If successful, this could show a faster, safer way to correct vitamin D deficiency in lymphoma patients, potentially improving overall treatment outcomes.
What could go wrong
This is a small, early-stage trial with only 52 participants. The high-dose regimen may cause side effects like high calcium levels, and faster vitamin D normalization may not translate to better lymphoma control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Phramonkutklao Hospital
Bangkok, 10400, Thailand
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact